- Trial phase
- Phase 1
- Time to market
- Unknown, pivotal study start is planned for 2027, meaning FDA approval would likely be several years away if Phase 2/3 data are positive.
- Why 5/10
- The next hard, dated catalyst is the ESMO 2026 proffered paper oral presentation of Phase 1 dose-expansion data (likely October 2026). This is Phase 1 data, not a pivotal readout, and Xencor has a broader pipeline of partnered and proprietary XmAb programs, so XmAb819 is not the company's sole value driver. ImpactScore is 5.
Watch the ESMO 2026 oral presentation (likely October 2026) for updated Phase 1 dose-expansion data, specifically whether the 25% ORR holds or improves in a larger cohort and whether the safety profile (primarily Grade 1-2 CRS, rash, GI events) remains manageable. The pivotal study start in 2027 is the next major milestone after that. XNCR's ~$26 stock price already reflects a mean analyst target of $29, limiting near-term upside absent a clear data beat.
Price Chart
Executive Summary
XmAb819 is a first-in-class ENPP3 x CD3 bispecific T-cell engager from Xencor (NASDAQ:XNCR), in Phase 1 testing for advanced clear cell renal cell carcinoma (ccRCC). Initial dose-escalation data showed a 25% objective response rate in heavily pretreated patients, meeting internal criteria to proceed to dose expansion. The drug is on track for a pivotal study start in 2027. Xencor trades at ~$26.20 with a market cap supported by a broader XmAb platform and partnered programs. The next catalyst is an ESMO 2026 oral presentation of updated Phase 1 data. While early efficacy is promising, the drug remains early-stage with a long path to market, and the stock already reflects a strong analyst consensus (17 Buy/Strong Buy out of 20 analysts) and a mean price target of $29 (8.8% upside).
How It Works
XmAb819 is a bispecific antibody, a single engineered molecule with two arms. One arm binds to ENPP3, a protein found on the surface of kidney cancer cells (clear cell renal cell carcinoma). The other arm grabs CD3, a protein on immune T-cells. This brings T-cells right up to the cancer cells, triggering the immune system to kill them. It uses Xencor's proprietary "2+1" format, which gives it two binding sites for the tumor target (for tighter grip) and one for the T-cell.
Trial Status
XmAb819 is in a multicenter, open-label Phase 1 study (NCT05433142) combining dose escalation and dose expansion. As of a September 19, 2025 data cut-off, 69 patients had received XmAb819 across 10 intravenous and 5 subcutaneous dose cohorts. Initial dose-escalation results were presented at the AACR-NCI-EORTC Conference in October 2025, showing a 25% objective response rate (ORR) in unselected, heavily pretreated clear cell renal cell carcinoma (ccRCC) patients. The drug met internal criteria to advance into the dose-expansion phase. A proffered paper oral presentation at ESMO 2026 has been accepted for updated Phase 1 results.
The Two-Sided Case
Upcoming Catalysts
- ESMO 2026 proffered paper oral presentation of updated Phase 1 dose-expansion data (likely October 2026)
- Pivotal study start planned for 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Xencor Inc 8-K XNCR ·Originating report